QR kód

Associations between good days per month and migraine-related disease impact in the real-world: a post hoc analysis from the REVIEW study of eptinezumab in chronic migraine

Abstract Background Data from the real-world REVIEW (Real-world EVidence and Insights into Experiences With eptinezumab) study demonstrated that, after starting treatment with eptinezumab, individuals with chronic migraine (CM) experienced double the number of good days per month and high rates of s...

Celý popis

Uloženo v:
Hlavní autoři: Fawad A. Khan, Steven P. Herzog, Ryan M. Smith, Dawn C. Buse, Seema Soni-Brahmbhatt, Susanne F. Awad, S. Wald Grossman, Divya Asher, Foram Patel, Charles Argoff
Médium: Artigo
Jazyk:Inglês
Vydáno: BMC 2025-11-01
Edice:The Journal of Headache and Pain
Témata:
Chronic migraine
Eptinezumab
Real-world
Good days per month
Brain fog
Cognition
On-line přístup:https://doi.org/10.1186/s10194-025-02227-5
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky